今年以来,开发减肥药的企业IPO热情很高,已有派格生物、银诺医药等相继上市,后面还有先为达生物、诚益生物、博瑞医药等在排队,颇有当年扎堆PD-1的势头。已经“上桌”的企业,都在八仙过海各显神通,努力不被挤下去。比如先为达生物剑走偏锋,做的是差异化的偏向型GLP-1受体激动剂。理论上,这条技术路线能精准打开治疗效果之门,同时尽量避免副作用。先为达生物的核心产品是埃诺格鲁肽注射液,减重及2型糖尿病...
Source Link今年以来,开发减肥药的企业IPO热情很高,已有派格生物、银诺医药等相继上市,后面还有先为达生物、诚益生物、博瑞医药等在排队,颇有当年扎堆PD-1的势头。已经“上桌”的企业,都在八仙过海各显神通,努力不被挤下去。比如先为达生物剑走偏锋,做的是差异化的偏向型GLP-1受体激动剂。理论上,这条技术路线能精准打开治疗效果之门,同时尽量避免副作用。先为达生物的核心产品是埃诺格鲁肽注射液,减重及2型糖尿病...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.